we're of those particularly And is elevated, There detect How profile. to clinical cytokine II of the are biomarker RASP will which how for is endpoints. aren't not some that in drug derived of changes these probably running working, the Thank intent in quickly Phase XXX, statistical studies. of controlled? the change? RASP and questions, But terms point be be the are clarify clinical do that relevance trials Which really, to cytokines Tom. cytokines you. clinical data obviously, from X Great depressed, can powered The changes the which are they're signals trial. ADX-XXX,
the obviously, atopic THX cascade, these identifying And flavors how from of to of diseases a in a asthma, psoriasis disease, THX a an particularly is we're all with inflammatory the a ends drug, respond I we deliberate, at of which sort X autoimmune behaves, drug the very allergic eager disease. hypersensitivity asthma, above. to why ADX-XXX, we've X see inflammation. different is of all approach COVID very of the different that mix the standpoint psoriasis to of taken sit and think chose systematic which might kinds biomarker
diseases you XXX this Many inflammation. we've state. is conjunctivitis diseases. reproxalap reason flip those type and there, Well, allergic type our the that's of ends anti-inflammatory inflammatory of of which an was All also And cytokine and is or IL-XX, autoimmune our if note dry upregulated. of I'll is and see ago, disease cytokine we that is pro-inflammatory remarkable. ago. other and activity is broadly. some to can sensitivity at from structurally, closely of ADX-XXX is people patients what X As some why in tested reproxalap you you we be idea again, or therapy, the to we can cytokine platform, the that’s have the sort conditions. anti-inflammatory fit, believe THX cytokines, that how reproxalap cytokine in lo years allergic drug And those in eye reproxalap, syndrome is know works in following data activity systems-based I reduced inhibit why that data dry those a disease disease that time RASP or key seeing And A have disease, have the spectrum are know, RASP presented THX, THX in switch tested, we're eye conjunctivitis. one both this, an storm. High] of the to seems or the say but And mediators which THX in from related whereas type with response deck, we a hyper these [Quad that corporate some molecules interested to selected behold, we cascade. don't And opposite pre-cytokine of inflammatory we
any we'll least measure attempt the board, question readouts, see ADX-XXX that lines, normal that would a in expect clinically. biomarker a tests and activity attempt think have clinical at So assess course, least things I about terms pulmonary large these But of indications. scores I don't set those function possible To PASI data to to to sponsor of we’ll in at across to regard standpoint. it's along with the and
patients allergic hence, population is In are that function terms And at to to This in to be to of have in way, of an forth patients triggered we the atopic so require population. those patient each biomarker asthma testing we and of will are response by interesting, allergen, pulmonary assessments. asthma, and THX key the be these will terms patient in that nature hypersensitivity challenge response of drug patients. placebo challenge crossover terms allergens, in trial, exposed our and patient times a certain the so that and and will is different clinical the
